Display Settings:

Format

Send to:

Choose Destination
    Pediatr Blood Cancer. 2011 Apr 29. doi: 10.1002/pbc.23154. [Epub ahead of print]

    Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program.

    Source

    Texas Tech University Health Sciences Center, Lubbock, Texas. min.kang@ttuhsc.edu.

    Abstract

    AT13387, a non-geldanamycin inhibitor of heat-shock protein 90 (HSP90), was tested against the PPTP in vitro panel (1.0 nM to 10 µM) and against the PPTP in vivo panels (40 or 60 mg/kg) administered orally twice weekly. In vitro AT13387 showed a median EC(50) value of 41 nM and exhibited activity consistent with a cytotoxic effect. In vivo AT13387 induced significant differences in EFS distribution compared to controls in 17% evaluable solid tumor xenografts, but in none of the ALL xenografts. No objective tumor responses were observed. In vivo AT13387 demonstrated only modest single agent activity. Pediatr Blood Cancer © 2011 Wiley-Liss, Inc.

    Copyright © 2011 Wiley-Liss, Inc.

    PMID:
    21538821
    [PubMed - as supplied by publisher]
    PMCID:
    PMC3154460
    [Available on 2012/10/29]

      Supplemental Content

      Click here to read

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk